share_log

Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts

Benzinga ·  May 8 02:00

In the last three months, 6 analysts have published ratings on Travere Therapeutics (NASDAQ:TVTX), offering a diverse range of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings32100
Last 30D10000
1M Ago11000
2M Ago10000
3M Ago01100

Analysts have set 12-month price targets for Travere Therapeutics, revealing an average target of $14.83, a high estimate of $19.00, and a low estimate of $9.00. Witnessing a positive shift, the current average has risen by 4.07% from the previous average price target of $14.25.

price target chart

Diving into Analyst Ratings: An In-Depth Exploration

An in-depth analysis of recent...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment